GlassScriptPhysician profile
Callie Powell
NPI 1730457250
$3,576.96
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $197 · 2022: $1,245 · 2023: $1,682 · 2024: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,055 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,054.55 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $473.27 | 2022-2024 | |
| Genzyme Corporation | $391.78 | 2021-2024 | |
| Lilly USA, LLC | $368.61 | 2022-2023 | Olumiant, Taltz |
| Arcutis Biotherapeutics, INC. | $266.41 | 2023-2024 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $255.86 | 2022-2024 | Sotyktu |
| Janssen Biotech, INC. | $255.48 | 2022-2023 | Simponi Aria, Tremfya |
| Journey Medical Corporation | $239.05 | 2022 | |
| Incyte Corporation | $238.66 | 2022-2024 | Opzelura |
| Pfizer INC. | $184.63 | 2023 | |
| Almirall LLC | $143.19 | 2022-2023 | Klisyri |
| Ucb, INC. | $135.02 | 2022-2023 | Cimzia |
| Biofrontera INC. | $124.03 | 2022-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Optinose US, INC. | $109.23 | 2021 | |
| Dermavant Sciences, INC. | $98.25 | 2024 | Vtama |
| Galderma Laboratories, L.P. | $70.28 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $53.54 | 2022-2023 | Libtayo |
| Novartis Pharmaceuticals Corporation | $47.91 | 2023-2024 | |
| Sun Pharmaceutical Industries INC. | $44.86 | 2022-2023 | Ilumya |
| Mayne Pharma Commercial LLC | $27.41 | 2023 | |
| Epi Health, LLC | $18.38 | 2022 | |
| Leo Pharma INC. | $16.03 | 2023 | Adbry |
| Glaxosmithkline, LLC. | $15.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Callie Powell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.